153 related articles for article (PubMed ID: 23083672)
21. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Fujita Y; Yoshioka N; Abe R; Murata J; Hoshina D; Mae H; Shimizu H
J Am Acad Dermatol; 2011 Jul; 65(1):65-8. PubMed ID: 21507517
[TBL] [Abstract][Full Text] [Related]
22. [Clinical assessment of the risk of bacteremia and the value of skin cultures during Stevens-Johnson syndrome and toxic epidermal necrolysis].
de Prost N; Duong TA; Brun-Buisson C; Roujeau JC
Ann Dermatol Venereol; 2010 Oct; 137(10):651-2. PubMed ID: 20932449
[No Abstract] [Full Text] [Related]
23. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
24. Severe cutaneous drug reactions: case reports.
Herold M; Oltmanns G; Duck HJ; Maru M
Ethiop Med J; 1983 Oct; 21(4):227-32. PubMed ID: 6194993
[No Abstract] [Full Text] [Related]
25. Corticosteroids in the treatment of skin disorders.
Wheeler CE; Briggaman RA; Puritz EM
Am Fam Physician; 1973 Jan; 7(1):130-40. PubMed ID: 4682971
[No Abstract] [Full Text] [Related]
26. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
27. [Lyell's and Stevens-Johnson syndromes].
Postovit VA; Khazak RS; Kunina TA
Ter Arkh; 1976; 48(11):126-33. PubMed ID: 1021888
[No Abstract] [Full Text] [Related]
28. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.
Schneck J; Fagot JP; Sekula P; Sassolas B; Roujeau JC; Mockenhaupt M
J Am Acad Dermatol; 2008 Jan; 58(1):33-40. PubMed ID: 17919775
[TBL] [Abstract][Full Text] [Related]
29. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
31. [Polymorphous exudative erythema, Stevens-Johnson syndrome and Lyell's syndrome. 30 pediatric ases followed in last 6 years].
Ulivelli A; Baldasseroni G; Petriccioli G
Riv Clin Pediatr; 1970; 83(1):31-51. PubMed ID: 5514865
[No Abstract] [Full Text] [Related]
32. [Interrelation of erythema multiforme exudativum and Lyell's and Stevens-Johnson syndromes].
Soloshenko EN
Vestn Dermatol Venerol; 1981 Jul; (7):30-2. PubMed ID: 7293470
[No Abstract] [Full Text] [Related]
33. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
[TBL] [Abstract][Full Text] [Related]
34. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
Aberer W; Stingl G; Wolff K
Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
[TBL] [Abstract][Full Text] [Related]
35. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
36. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
37. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
Bastuji-Garin S; Rzany B; Stern RS; Shear NH; Naldi L; Roujeau JC
Arch Dermatol; 1993 Jan; 129(1):92-6. PubMed ID: 8420497
[TBL] [Abstract][Full Text] [Related]
38. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
39. The EuroSCAR study: cannot agree with the conclusions.
Pehr K
J Am Acad Dermatol; 2008 Nov; 59(5):898-9; author reply 899-900. PubMed ID: 19119105
[No Abstract] [Full Text] [Related]
40. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
